Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1043]

New cancer subtype may illuminate treatment strategy

New cancer subtype may illuminate treatment strategy

ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN research highlights at ASCO 2022

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast...

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+ breast cancer, study finds

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+...

Common prostate cancer medications may be less safe than previously thought

Common prostate cancer medications may be less safe than previously thought

Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer

Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

ecancer are launching a new initiative to improve cancer care in low-income countries with support from Bristol Myers Squibb

ecancer are launching a new initiative to improve cancer care in low-income countries with support from Bristol...

Trial results indicate trametinib should represent the new standard of care for women with recurrent low-grade serous ovarian cancer

Trial results indicate trametinib should represent the new standard of care for women with recurrent low-grade...

Widely-used hormone drug associated with increased risk of benign brain tumour at high doses

Widely-used hormone drug associated with increased risk of benign brain tumour at high doses

More from ecancer